Arca Biopharma Inc  

(Public, NASDAQ:ABIO)   Watch this stock  
0.00 (0.00%)
Sep 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.15 - 1.20
52 week 1.05 - 3.00
Open 1.15
Vol / Avg. 43,968.00/109,790.00
Mkt cap 14.92M
P/E     -
Div/yield     -
EPS -2.05
Shares 12.97M
Beta 1.96
Inst. own 44%
Nov 13, 2017
Q3 2017 ARCA Biopharma Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 3, 2017
Q2 2017 ARCA Biopharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -116.93% -51.23%
Return on average equity -135.12% -54.57%
Employees 20 -
CDP Score - -


11080 Circle Point Rd Ste 140
WESTMINSTER, CO 80020-2769
United States - Map
+1-720-9402200 (Phone)
+1-720-2089261 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Officers and directors

Robert E. Conway Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Michael R. Bristow M.D., Ph.D. President, Chief Executive Officer, Director
Age: 71
Bio & Compensation  - Reuters
Thomas A. Keuer Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Christopher David Ozeroff Senior Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Brian L. Selby CPA Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Linda S. Grais M.D. Lead Independent Director
Age: 61
Bio & Compensation  - Reuters
Anders D. Hove M.D. Director
Age: 50
Bio & Compensation  - Reuters
Daniel J. Mitchell Director
Age: 58
Bio & Compensation  - Reuters
Raymond L. Woosley M.D., Ph.D. Director
Age: 72
Bio & Compensation  - Reuters